Curated News
By: NewsRamp Editorial Staff
July 07, 2025
Tonix Pharmaceuticals to Reveal TNX-801 Vaccine Data at Vaccine Congress 2025
TLDR
- Tonix Pharmaceuticals' TNX-801 vaccine candidate offers a strategic advantage in biodefense and public health with its potential to protect against mpox and other orthopoxviruses.
- TNX-801, a recombinant horsepox virus live vaccine, demonstrates protective efficacy in animal models with a single dose, aiming for durable immune responses against orthopoxviruses.
- Tonix Pharmaceuticals' development of TNX-801 represents a significant step towards improving global health security by addressing emerging viral threats with innovative vaccine technology.
- Discover how Tonix Pharmaceuticals is pioneering with TNX-801, a vaccine that could revolutionize our defense against mpox and other dangerous viruses.
Impact - Why it Matters
The development of TNX-801 by Tonix Pharmaceuticals represents a critical advancement in vaccine technology, offering hope for effective protection against mpox and other orthopoxviruses. This is particularly relevant in a world increasingly faced with emerging viral threats. Additionally, Tonix's broader efforts in pain management and public health, including the potential FDA approval of TNX-102 SL for fibromyalgia, highlight the company's role in addressing some of today's most pressing health challenges. Their work not only has the potential to save lives but also to improve the quality of life for millions suffering from chronic conditions and infectious diseases.
Summary
Tonix Pharmaceuticals (NASDAQ: TNXP), a leader in biopharmaceutical innovation, is set to unveil groundbreaking preclinical data on TNX-801, a promising vaccine candidate, at the Vaccine Congress 2025 in Vienna. Dr. Sina Bavari, the company's Executive Vice President of Infectious Disease Research and Development, will present findings that underscore TNX-801's potential to combat mpox and other orthopoxviruses with a single dose, showcasing its safety, immunogenicity, and efficacy. This development marks a significant step forward in the fight against emerging viral threats, with clinical trials on the horizon. Tonix Pharmaceuticals is also making strides in pain management and public health, with TNX-102 SL for fibromyalgia nearing FDA submission and a $34 million contract from the U.S. Department of Defense to develop antiviral agents. For more details, visit the full press release.
Tonix Pharmaceuticals is not just about vaccines; it's a multifaceted company with a robust portfolio spanning CNS disorders, immunology, rare diseases, and infectious diseases. Its commercial subsidiary, Tonix Medicines, markets treatments for acute migraine, further demonstrating the company's commitment to addressing critical health challenges. With state-of-the-art facilities and a pipeline of innovative therapies, Tonix is at the forefront of medical research and development. Learn more about their work at www.TonixPharma.com.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Tonix Pharmaceuticals to Reveal TNX-801 Vaccine Data at Vaccine Congress 2025
